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We are researchers and clinicians working on
Alzheimer’s disease (AD) or related topics, and we
write to express our concern that one particular aspect
of the disease has been neglected, even though treat-
ment based on it might slow or arrest AD progression.
We refer to the many studies, mainly on humans,
implicating specific microbes in the elderly brain,
notably herpes simplex virus type 1 (HSV1), Chlamy-
dia pneumoniae, and several types of spirochaete, in
the etiology of AD [1–4]. Fungal infection of AD
brain [5, 6] has also been described, as well as abnor-
mal microbiota in AD patient blood [7]. The first
observations of HSV1 in AD brain were reported
almost three decades ago [8]. The ever-increasing
number of these studies (now about 100 on HSV1
alone) warrants re-evaluation of the infection and AD
concept.
AD is associated with neuronal loss and pro-
gressive synaptic dysfunction, accompanied by the
deposition of amyloid- (A) peptide, a cleavage
product of the amyloid- protein precursor (APP),
and abnormal forms of tau protein, markers that have
been used as diagnostic criteria for the disease [9, 10].
These constitute the hallmarks of AD, but whether
they are causes of AD or consequences is unknown.
We suggest that these are indicators of an infectious
etiology. In the case of AD, it is often not realized
that microbes can cause chronic as well as acute dis-
eases; that some microbes can remain latent in the
body with the potential for reactivation, the effects
of which might occur years after initial infection;
and that people can be infected but not necessarily
affected, such that ‘controls’, even if infected, are
asymptomatic [2].
EVIDENCE FOR AN INFECTIOUS/IMMUNE
COMPONENT
(i) Viruses and other microbes are present in
the brain of most elderly people [11–13].
Although usually dormant, reactivation can
occur after stress and immunosuppression; for
example, HSV1 DNA is amplified in the brain
of immunosuppressed patients [14].
(ii) Herpes simplex encephalitis (HSE) produces
damage in localized regions of the CNS related
to the limbic system, which are associated
with memory, cognitive and affective processes
[15], as well as personality (the same as those
affected in AD).
(iii) In brain of AD patients, pathogen signatures
(e.g., HSV1 DNA) specifically colocalize with
AD pathology [13, 16, 17].
(iv) HSV infection, as revealed by seropositivity,
is significantly associated with development of
AD [18–21].
(v) AD has long been known to have a promi-
nent inflammatory component characteristic of
infection (reviewed in [22, 23]).
(vi) Polymorphisms in the apolipoprotein E gene,
APOE, that modulate immune function and
susceptibility to infectious disease [24], also
govern AD risk (reviewed in [25, 26]).
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Genome-wide association studies reveal that
other immune system components, including
virus receptor genes, are further AD risk factors
[27–32].
(vii) Features of AD pathology are transmissible by
inoculation of AD brain to primates [33, 34]
and mice [35, 36].
EVIDENCE FOR CAUSATION
(i) In humans, brain infection (e.g., by HIV, her-
pesvirus, measles) is known to be associated
with AD-like pathology [37–42]. Historical
evidence shows that the clinical and patholog-
ical hallmarks of AD occur also in syphilitic
dementia, caused by a spirochaete [4].
(ii) In mice and in cell culture, A deposition and
tau abnormalities typical of AD are observed
after infection with HSV1 [43–52] or bacte-
ria [16, 53–55]; a direct interaction between
APP and HSV1 has been reported [56].
Antivirals, including acyclovir, in vitro block
HSV1-induced A and tau pathology [57].
(iii) Olfactory dysfunction is an early symptom of
AD [58]. The olfactory nerve, which leads
to the lateral entorhinal cortex, the initial site
from where characteristic AD pathology sub-
sequently spreads through the brain [59, 60], is
a likely portal of entry of HSV1 [61] and other
viruses [62], as well asChlamydia pneumoniae,
into the brain [63], implicating such agents
in damage to this region. Further, brainstem
areas that harbor latent HSV directly irrigate
these brain regions: brainstem virus reactiva-
tion would thus disrupt the same tissues as those
affected in AD [64].
GROWING EVIDENCE FOR
MECHANISM: ROLE OF A
(i) The gene encoding cholesterol 25-hydroxylase
(CH25H) is selectively upregulated by virus
infection, and its enzymatic product (25-
hydroxycholesterol, 25OHC) induces innate
antiviral immunity [65, 66].
(ii) Polymorphisms in human CH25H govern both
AD susceptibility and A deposition [67],
arguing that A induction is likely to be among
the targets of 25OHC, providing a potential
mechanistic link between infection and Apro-
duction [68].
(iii) A is an antimicrobial peptide with potent
activity against multiple bacteria and yeast
[69]. A also has antiviral activity [70–72].
(iv) Another antimicrobial peptide (-defensin 1) is
upregulated in AD brain [73].
Regarding HSV1, about 100 publications by many
groups indicate directly or indirectly that this virus
is a major factor in the disease. They include studies
suggesting that the virus confers risk of the disease
when present in brain of carriers of the 4 allele of
APOE [74], an established susceptibility factor for
AD (APOE 4 determines susceptibility in several
disorders of infectious origin [75], including herpes
labialis, caused usually by HSV1). The only oppos-
ing reports, two not detecting HSV1 DNA in elderly
brains and another not finding an HSV1–APOE asso-
ciation, were published over a decade ago [76–78].
However, despite all the supportive evidence, the
topic is often dismissed as ‘controversial’. One recalls
the widespread opposition initially to data showing
that viruses cause some types of cancer, and that a
bacterium causes stomach ulcers.
In summary, we propose that infectious agents,
including HSV1, Chlamydia pneumonia, and spiro-
chetes, reach the CNS and remain there in latent form.
These agents can undergo reactivation in the brain
during aging, as the immune system declines, and dur-
ing different types of stress (which similarly reactivate
HSV1 in the periphery). The consequent neuronal
damage—caused by direct viral action and by virus-
induced inflammation—occurs recurrently, leading
to (or acting as a cofactor for) progressive synaptic
dysfunction, neuronal loss, and ultimately AD. Such
damage includes the induction of Awhich, initially,
appears to be only a defense mechanism.
AD causes great emotional and physical harm to
sufferers and their carers, as well as having enor-
mously damaging economic consequences. Given the
failure of the 413 trials of other types of therapy for
AD carried out in the period 2002–2012 [79], antivi-
ral/antimicrobial treatment of AD patients, notably
those who are APOE 4 carriers, could rectify the
‘no drug works’ impasse. We propose that further
research on the role of infectious agents in AD cau-
sation, including prospective trials of antimicrobial
therapy, is now justified.
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